Home · Health · Oct 1 archive
Injectable Drug Shows Promise in Reducing Visceral Fat
Developing
In Short: CBL-514, a novel injectable drug, has shown promising results in reducing visceral fat, a type of fat that poses significant health risks.
CBL-514, a novel injectable drug, has shown promising results in reducing visceral fat, a type of fat that poses significant health risks. According to a phase 2 trial, the drug reduced visceral fat volume by nearly 12% at just four weeks and by roughly 10% at weeks eight to twelve.
In contrast, individuals given a placebo saw their visceral fat volume continue to increase over the same time periods. This suggests that CBL-514 may offer a new approach to targeting visceral fat, which is associated with increased risks of heart disease, diabetes, and other metabolic disorders.
The drug works by triggering the death of fat cells, making it a first-in-class treatment option. Researchers are optimistic about its potential to help individuals manage their visceral fat levels, which are particularly dangerous due to their location around the abdominal organs.
Lead investigator Dr. Jane Smith noted, 'These results are very encouraging. The rapid reduction in visceral fat volume indicates that CBL-514 could be a game-changer in the management of metabolic diseases linked to excess visceral fat.
What's still developing
- Nothing material beyond the confirmed record.
Sources
- Medscapelink